RYTM — RHYTHM PHARMACEUTICALS, INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1649904 ·
Last close
$98.66
Market Cap
$6.79B
52W High
$122.20
52W Low
$74.50
ADV30
562,683
Next earnings
2026-11-03
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 71,255,000 | 62,324,000 | -48,552,000 | -49,298,000 | 437,266,000 | 65,614,000 | 219,965,000 |
| Mar 2026 | 60,112,000 | 52,955,000 | -52,361,000 | -55,639,000 | 442,316,000 | 62,137,000 | 204,700,000 |
| Dec 2025 | 57,253,000 | 52,451,000 | -47,063,000 | -47,505,000 | 480,196,000 | 54,301,000 | 210,170,000 |
| Sep 2025 | 51,298,000 | 45,799,000 | -52,653,000 | -52,904,000 | 506,874,000 | 52,078,000 | 211,191,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-105,348,000
Investing CF
$-144,935,000
Financing CF
$179,788,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.11
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,456,814,000
Inventory
$30,517,000
Receivables
$40,408,000
ST Investments
$265,283,000
EBIT TTM
$-185,797,000
Pretax Income TTM
$-204,277,000
Interest Exp TTM
$18,480,000
Analysts
15
Yahoo Snapshot (yfinance, live)
Total Revenue
$239,918,000
EBITDA
$-199,550,000
Free Cash Flow
$-130,588,128
Enterprise Value
$7,102,706,688
Total Cash
$330,896,992
Total Debt
$109,784,000
Shares Out
68,852,082
Trailing EPS
$-3.12
Book Value
$1.50
ROE
-117.0%
ROA
-31.0%
Div Yield
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 189,757,000 | -192,016,000 | -196,539,000 | 480,196,000 | 210,170,000 | 270,026,000 | -115,675,000 |
| Dec 2024 | 130,126,000 | -265,503,000 | -260,602,000 | 392,273,000 | 227,724,000 | 164,549,000 | -113,879,000 |
| Dec 2023 | 77,428,000 | -184,357,000 | -184,678,000 | 332,745,000 | 162,986,000 | 169,759,000 | -136,157,000 |
| Dec 2022 | 23,638,000 | -179,157,000 | -181,119,000 | 382,481,000 | 118,219,000 | 264,262,000 | -173,428,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.61
Max Pain — expiry 2027-01-15
max pain strike: $90.00 · spot: $95.60 · call oi: 1,414 · put oi: 445
Expected Move to 2027-01-15:
±$16.85
(17.63%) —
implied range
$78.75 –
$112.45
· ATM straddle on $95.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| BLTE | BELITE BIO, INC | $6.74B | $167.33 | — |
| ALKS | Alkermes plc. | $6.85B | $40.85 | — |
| AMRX | Amneal Pharmaceuticals, Inc. | $6.89B | $19.77 | — |
| IONS | IONIS PHARMACEUTICALS INC | $7.40B | $44.50 | — |
| LQDA | Liquidia Corp | $6.13B | $68.43 | — |
News headlines (Yahoo Finance, 1h cache)
Rhythm Pharmaceuticals Announces Health Canada Approval of IMCIVREE® (setmelanotide) for Weight Management in Adult and Pediatric Patients 4 years of Age and Older with Acquired Hypothalamic Obesity
2026-09-22 12:00 · Yahoo
Billionaire Stanley Druckenmiller’s 2 New Healthcare Stock Picks
2026-09-11 12:47 · Yahoo
Rhythm Pharmaceuticals (RYTM) Stock Looks Overvalued Despite Its 7x Five Year Run
2026-08-26 10:15 · Yahoo
Eli Lilly and Novo Nordisk Can't Treat This Form of Obesity. Billionaire Stanley Druckenmiller Is Betting Rhythm Pharmaceuticals Can
2026-08-23 22:20 · Yahoo
Rhythm Pharmaceuticals Eyes AHO Growth, Global IMCIVREE Expansion and Pipeline Catalysts
2026-08-17 06:01 · Yahoo
Rhythm Pharmaceuticals (RYTM) Q2 2026 Earnings Call Transcript
2026-08-11 16:44 · Yahoo
Rhythm Pharmaceuticals Announces IMCIVREE® (setmelanotide) Receives Expanded Marketing Authorization in the United Kingdom for Treatment of Obesity and Control of Hunger in Patients with Acquired Hypo
2026-08-11 12:00 · Yahoo
Ultragenyx (RARE) Surges 12.6%: Is This an Indication of Further Gains?
2026-09-18 11:28 · Yahoo
Rhythm Pharmaceuticals Announces New Data Presentations at the European Society for Paediatric Endocrinology Meeting
2026-09-10 12:00 · Yahoo
Moderna upgraded, Allstate downgraded: Wall Street's top analyst calls
2026-08-28 13:38 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.